(PRWEB) March 29, 2006
Dr. Joe Artiss, VP ArtJen Complexus Holdings Corp. discussed FBCx, the diet pill that is said to have Detroit talking, with Barbara Peacock on CBC Windsor Radio Cross Town program.
FBCx was included as part of the week-long report on obesity that the Canadian Broadcasting Corporation stations were airing. Ms. Peacock’s interview with Dr. Artiss, discussing the benefits of FBCx relative to other weight loss products and programs, is available on the ArtJen website http://www.fbcx.com under Breaking News. Dubbed the “Fat Fighter” in recent coverage by the Detroit Fox TV Network and said to be showing “huge potential” by Canadian print media, ArtJen Complexus Holdings Corp. is pleased that FBCx continues to show more positive effects than any competing pharmaceutical or nutraceutical weight loss products.
George Grunberger, M.D., K-L Catherine Jen, Ph.D. and Joseph Artiss, Ph.D. recently presented the findings of their clinical trial on obese volunteers with type 2 diabetes at both the June meeting of the American Diabetes Association and the October meeting of the North American Association for the Study of Obesity. The investigators expect that their data will soon be available to the medical and scientific communities in a peer-reviewed journal. The impressive results from the double-blind, placebo controlled clinical trial include:
FBCx is effective in reducing and/or maintaining body weight in patients with type 2 diabetes.
FBCx is effective in reducing blood cholesterol and triglyceride levels in patients with elevated lipids.
FBCx can easily be incorporated into anybody’s weight management regimen.
FBCx was shown to bind 9 times its own weight in dietary fat in human volunteers.
FBCx is effective for weight management.
Although skeptical at first Dr Grunberger now states that: “It’s safe, it does not interfere with any other medication my patients may be taking. And it seems to address my patients’ major concerns that not only are they obese, but that they can’t seem to lose weight.”. Dr Grunberger continued, “This discovery, which can help shed pounds or prevent weight gain, is real progress.” Dr Jen was quoted as saying that, “If FBCx works for obese diabetics it will work for anybody.”
The important results of this clinical trial could change dietary management in patients with type 2 diabetes. Subjects in preclinical trials, including non-diabetic patients showed dramatic and consistent weight loss. Consisting of a specific all natural fiber, each 1 gram tablet binds 9 grams of dietary fat, effectively preventing the fat from being absorbed by the body.
The recommended 2 tablets per meal typically results in a weight loss of 4 to 6 pounds per month. The product is now available under the FBCx trademark. A US patent has been awarded to ArtJen for FBCx; worldwide patents are pending.
# # #